Article
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Bioorganic & medicinal chemistry - 1 Oct 2022
Imaizumi Tomoyoshi, Akaiwa Michinori, Abe Tomoaki, Nigawara Takahiro, Koike Takanori, Satake Yoshiki, Watanabe Kazushi, Kaneko Osamu, Amano Yasushi, Mori Kenichi, Yamanaka Yosuke, Nagashima Takeyuki, Shimazaki Masashi, Kuramoto Kazuyuki
Abstract excerpt
RAS protein plays a key role in cellular proliferation and differentiation. RAS gene mutation is a known driver of oncogenic alternation in human cancer. RAS inhibition is an effective therapeutic treatment for solid tumors, but RAS protein has been classified as an undruggable target. Recent reports have demonstrated that a covalent binder to KRAS protein at a mutated cysteine residue (G12C) is effective for the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
